Cadila’s Changodar unit gets Establishment Inspection report from USFDA

Cadila Healthcare’s topical manufacturing facility located at Changodar in Ahmedabad has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (US FDA) following the inspection carried out in March 2016. The receipt of EIR indicates the successful closure of the inspection points (483s) raised. The topical plant is a dedicated facility for manufacturing ointments and does not form a part of the Moraiya formulations manufacturing plant.

Cadila Healthcare is part of the Zydus Cadila Group. The company operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world.